Skip to main content

Table 5 Predictors of pneumonia in RA patients by the Cox-hazard model (univariate analysis)

From: The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial

  Hazard ratio P value 95% CI
Demographics
 Age (years) 1.058 0.002 1.021–1.095
 Gender, male 1.073 0.870 0.464–2.480
Laboratory data
 CRP (mg/dl) 1.321 <0.0001 1.140–1.531
 Serum albumin (g/dl) 0.414 0.051 0.171–1.004
 Serum creatinine (mg/dl) 1.358 0.413 0.652–2.828
RA characteristics
 RA duration (years) 1.002 0.927 0.968–1.036
 HAQ 1.219 0.366 0.794–1.871
 DAS28 (CRP) 0.894 0.498 0.646–1.237
 SDAI 0.970 0.281 0.919–1.025
 CDAI 0.949 0.115 0.890–1.013
Comorbidity
 Smoking history 0.936 0.877 0.405–2.165
 Cardiovascular disease 1.745 0.122 0.862–3.533
 Metabolic disease 1.612 0.211 0.763–3.405
 CKD 1.814 0.415 0.433–7.592
 Autoimmune disease 0.723 0.750 0.099–5.299
 Interstitial pneumonia 4.449 <0.0001 2.143–9.237
PPSV23 vaccination 1.048 0.894 0.523–2.099
Treatment
 PSL 1.314 0.443 0.654–2.643
 Dose of prednisolone (mg/day) 1.117 0.102 0.978–1.276
 MTX 0.778 0.493 0.381–1.593
 Dose of MTX (mg/week) 0.962 0.634 0.821–1.128
 TAC 0.956 0.934 0.335–2.727
 Biologics 0.544 0.088 0.270–1.094
  1. PPSV23 23-valent pneumococcal polysaccharide vaccine, CRP C-reactive protein, RA rheumatoid arthritis, HAQ Health Assessment Questionnaire Disability Index score, DAS28 Disease Activity Score 28, SDAI simplified disease activity index, CDAI clinical disease activity index, CKD chronic kidney disease, PSL prednisolone, MTX methotrexate, TAC tacrolimus, CI confidence interval